Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 3, 2006, Pages 539-557

  Akkoc, Nurullah ^a   van der Linden, Sjef ^b   Khan, Muhammad Asim ^c  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c METROHEALTH MEDICAL CENTER   (United States)

Author keywords

adverse effects; ankylosing spondylitis; corticosteroids; disease modification; DMARDs; drug therapy; management; NSAIDs; treatment

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; LEFLUNOMIDE; LIDOCAINE; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PARACETAMOL; PLACEBO; PREDNISOLONE; PROSTACYCLIN; PROTON PUMP INHIBITOR; ROFECOXIB; SALAZOSULFAPYRIDINE; SODIUM CHLORIDE; SULFAPYRIDINE; THALIDOMIDE; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL PAIN; ANALGESIA; ANKYLOSING SPONDYLITIS; ARTHRALGIA; ATHEROSCLEROSIS; BONE PAIN; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; EXERCISE; FATIGUE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; HEADACHE; HEART INFARCTION; HIP RADIOGRAPHY; HUMAN; HYPERTENSION; HYPOCALCEMIA; INDIVIDUALIZATION; INJECTION SITE REACTION; INTERSTITIAL NEPHRITIS; LYMPHOCYTOPENIA; MOBILIZATION; MUSCLE STIFFNESS; MYALGIA; NAUSEA AND VOMITING; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PARESTHESIA; PATIENT EDUCATION; PATIENT SELECTION; PHYSICAL CAPACITY; PHYSIOTHERAPY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SPINE MOBILITY; SPINE RADIOGRAPHY; SYMPTOM; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL RESPONSE MODIFIERS; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPONDYLITIS, ANKYLOSING;

EID: 33744915526     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.03.003     Document Type: Review

References (96)

1. Khan M.A. Update on spondyloarthropathies. Annals of Internal Medicine 136 (2002) 896-907
2. van der Linden S.M., van der Heijde D., and Braun J. Spondyloarthropathies. Ankylosing spondylitis. In: Harris E.D., Budd R.C., Firestein G.S., et al. (Eds). Kelley's Textbook of Rheumatology. 7th edn vol. 2 (2004), WB Saunders/Elsevier, Philadelphia 1135-1141
3. Boonen A., de Vet H., van der Heijde D., and van der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. The Journal of Rheumatology 28 (2001) 1056-1062
4. Ward M.M. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis and Rheumatism 46 (2002) 223-231
5. Boonen A., van der Heijde D., Landewe R., et al. Work status and productivity costs due to ankylosing spondylitis: comparison of three European countries. Annals of the Rheumatic Diseases 61 (2002) 429-437
6. Mau W., Listing J., Huscher D., et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. The Journal of Rheumatology 32 (2005) 721-728
7. Khan M.A., and Skosey J.L. Ankylosing spondylitis and related spondylarthropathies. In: M S (Ed). Immunological Diseases (1988), Little, Brown & Co, Boston 1509-1538
8. Edmonds J. DC-ART: the concept. The Journal of Rheumatology 41 supplement (1994) 3-5 (see discussion pages 5-7)
9. van der Heijde D., Bellamy N., Calin A., et al. Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in ankylosing spondylitis working group. The Journal of Rheumatology 24 (1997) 2225-2229
10. van der Heijde D., Calin A., Dougados M., et al. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS working group. Assessments in ankylosing spondylitis. The Journal of Rheumatology 26 (1999) 951-954
11. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis and Rheumatism 44 (2001) 1876-1886
12. van Tubergen A., van der Heijde D., Anderson J., et al. Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Annals of the Rheumatic Diseases 62 (2003) 215-221
13. Zochling J., van der Heijde D., Burgos-Vargas R., et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Annals of the Rheumatic Diseases 65 (2006) 442-452
14. Gossec L., van der Heijde D., Melian A., et al. Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Annals of the Rheumatic Diseases 64 (2005) 1563-1567
15. Fries J.F., Murtagh K.N., Bennett M., et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis and Rheumatism 50 (2004) 2433-2440
16. Singh G., and Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, rheumatism, and aging medical information system. The Journal of Rheumatology 51 supplement (1998) 8-16
17. Solomon D.H. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis and Rheumatism 52 (2005) 1968-1978
18. Zhang W., Doherty M., Arden N., et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT). Annals of the Rheumatic Diseases 64 (2005) 669-681
19. Deeks J.J., Smith L.A., and Bradley M.D. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ (Clinical research ed. ) 325 (2002) 619
20. Hall F.C., and Dalbeth N. Disease modification and cardiovascular risk reduction: two sides of the same coin?. Rheumatology 44 (2005) 1473-1482
21. Peters M.J., van der Horst-Bruinsma I.E., Dijkmans B.A., and Nurmohamed M.T. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Seminars in Arthritis and Rheumatism 34 (2004) 585-592
22. Sari I., Okan T., Akar S., et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology 45 (2006) 283-286
23. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. The New England Journal of Medicine 343 (2000) 1520-1528 [see also two pages following 1528]
24. Bolten W.W. Problem of the atherothrombotic potential of non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases 65 (2006) 7-13
25. Fitzgerald G.A. Coxibs and cardiovascular disease. The New England Journal of Medicine 351 (2004) 1709-1711
26. Fitzgerald GA. Mechanism Based Adverse Cardiovascular Events and Specific Inhibitors of COX-2. http://www.fda.gov/ohrms/dockets/AC/05/slides/2005-4090S1_03_FDA-Fitzgerald.ppt. Last accessed 11 January 2006.
27. Fischer L.M., Schlienger R.G., Matter C.M., et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Archives of Internal Medicine 164 (2004) 2472-2476
28. FitzGerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nature Reviews. Drug discovery 2 (2003) 879-890
29. Farkouh M.E., Kirshner H., Harrington R.A., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364 (2004) 675-684
30. Laine L., Maller E.S., Yu C., et al. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127 (2004) 395-402
31. Solomon S.D., McMurray J.J., Pfeffer M.A., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. The New England Journal of Medicine 352 (2005) 1071-1080
32. Graham D.J., Campen D., Hui R., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365 (2005) 475-481
33. Wanders A., Heijde D., Landewe R., et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis and Rheumatism 52 (2005) 1756-1765
34. Boersma J.W. Retardation of ossification of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone. Scandinavian Journal of Rheumatology 5 (1976) 60-64
35. Ward M.M. Prospects for disease modification in ankylosing spondylitis: do nonsteroidal antiinflammatory drugs do more than treat symptoms?. Arthritis and Rheumatism 52 (2005) 1634-1636
36. Zhang W., Jones A., and Doherty M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Annals of the Rheumatic Diseases 63 (2004) 901-907
37. Paulus H.E., and Bulpitt K.J. DC-ART classification: review of relevant clinical studies. The Journal of Rheumatology 41 supplement (1994) 8-20 [see also discussion pages 20-22]
38. Wanders A.J., Gorman J.D., Davis J.C., et al. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis. Arthritis and Rheumatism 51 (2004) 1-8
39. Ruof J., and Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. The Journal of Rheumatology 26 (1999) 966-970
40. van der Heijde D., Dougados M., Davis J., et al. Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis. Arthritis and Rheumatism 52 (2005) 386-394
41. Dougados M., Dijkmans B., Khan M., et al. Conventional treatments for ankylosing spondylitis. Annals of the Rheumatic Diseases 61 supplement 3 (2002) iii40-iii50
42. Maksymowych W.P., Breban M., and Braun J. Ankylosing spondylitis and current disease-controlling agents: do they work?. Best Practice & Research. Clinical Rheumatology 16 (2002) 619-630
43. Marzo-Ortega H., Emery P., and McGonagle D. The concept of disease modification in spondyloarthropathy. The Journal of Rheumatology 29 (2002) 1583-1585
44. Food and Drug Administration Center for Drug Evaluation and Research Meeting of the Arthritis Advisory Committee, 24 June 2003. http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3967T2.htm. Last accessed 11 January 2006.
45. Boulos P., Dougados M., Macleod S.M., and Hunsche E. Pharmacological treatment of ankylosing spondylitis: a systematic review. Drugs 65 (2005) 2111-2127
46. Maksymowych W.P., Inman R.D., Gladman D., et al. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. The Journal of Rheumatology 30 (2003) 1356-1363
47. Zochling J., van der Heijde D., Dougados M., and Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Annals of the Rheumatic Diseases 65 (2006) 423-432
48. Ferraz M.B., Tugwell P., Goldsmith C.H., and Atra E. Meta-analysis of sulfasalazine in ankylosing spondylitis. The Journal of Rheumatology 17 (1990) 1482-1486
49. Chen J., and Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database of Systematic Reviews (2005) CD004800
50. Clegg D.O., Reda D.J., Weisman M.H., et al. Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A department of veterans affairs cooperative study. Arthritis and Rheumatism 39 (1996) 2004-2012
51. Dougados M., vam der Linden S., Leirisalo-Repo M., et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis and Rheumatism 38 (1995) 618-627
52. Feltelius N., and Hallgren R. Sulphasalazine in ankylosing spondylitis. Annals of the Rheumatic Diseases 45 (1986) 396-399
53. Kirwan J., Edwards A., Huitfeldt B., et al. The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. British Journal of Rheumatology 32 (1993) 729-733
54. Nissila M., Lehtinen K., Leirisalo-Repo M., et al. Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis and Rheumatism 31 (1988) 1111-1116
55. Dougados M., Boumier P., and Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. BMJ (Clinical research ed. ) 293 (1986) 911-914
56. Schmidt W.A., Wierth S., Milleck D., et al. Sulfasalazine in ankylosing spondylitis: a prospective, randomized, double-blind placebo-controlled study and comparison with other controlled studies. Zeitschrift fur Rheumatologie 61 (2002) 159-167
57. Braun J., Allen R., Burmester G., et al. Efficacy of sulfasalazine in undifferentiated spondyloarthritis and early ankylosing spondylitis-a multicenter randomized controlled trial. Annals of the Rheumatic Diseases 63 (2004) 413
58. Neumann V.C., Taggart A.J., Le Gallez P., et al. A study to determine the active moiety of sulphasalazine in rheumatoid arthritis. The Journal of Rheumatology 13 (1986) 285-287
59. Taggart A., Gardiner P., McEvoy F., et al. Which is the active moiety of sulfasalazine in ankylosing spondylitis? A randomized, controlled study. Arthritis and Rheumatism 39 (1996) 1400-1405
60. Thomson G.T., Thomson B.R., Thomson K.S., and Ducharme J.S. Clinical efficacy of mesalamine in the treatment of the spondyloarthropathies. The Journal of Rheumatology 27 (2000) 714-718
61. Dekker-Saeys B.J., Dijkmans B.A., and Tytgat G.N. Treatment of spondyloarthropathy with 5-aminosalicylic acid (mesalazine): an open trial. The Journal of Rheumatology 27 (2000) 723-726
62. van Denderen J.C., van der Horst-Bruinsma I., Bezemer P.D., and Dijkmans B.A. Efficacy and safety of mesalazine (Salofalk) in an open study of 20 patients with ankylosing spondylitis. The Journal of Rheumatology 30 (2003) 1558-1560
63. Sari I., Birlik M., Cavdar C., et al. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy. The New Zealand Medical Journal 118 (2005) U1662
64. Sampaio-Barros P.D., Costallat L.T., Bertolo M.B., et al. Methotrexate in the treatment of ankylosing spondylitis. Scandinavian Journal of Rheumatology 29 (2000) 160-162
65. Biasi D., Carletto A., Caramaschi P., et al. Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clinical Rheumatology 19 (2000) 114-117
66. Roychowdhury B., Bintley-Bagot S., Bulgen D.Y., et al. Is methotrexate effective in ankylosing spondylitis?. Rheumatology 41 (2002) 1330-1332
67. Altan L., Bingol U., Karakoc Y., et al. Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scandinavian Journal of Rheumatology 30 (2001) 255-259
68. Chen J., and Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database of Systematic Reviews (2004) CD004524
69. Gonzalez-Lopez L., Garcia-Gonzalez A., Vazquez-Del-Mercado M., et al. Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. The Journal of Rheumatology 31 (2004) 1568-1574
70. Haibel H., Rudwaleit M., Braun J., and Sieper J. Six months open label trial of leflunomide in active ankylosing spondylitis. Annals of the Rheumatic Diseases 64 (2005) 124-126
71. Van Denderen J.C., Van der Paardt M., Nurmohamed M.T., et al. Double-blind, randomised, placebo-controlled study of leflunomide in the treatment of active ankylosing spondylitis. Annals of the Rheumatic Diseases 64 (2005) 1761-1764
72. Cairns A.P., Wright S.A., Taggart A.J., et al. An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Annals of the Rheumatic Diseases 64 (2005) 338-339
73. Haibel H., Brandt J., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42 (2003) 1018-1020
74. Maksymowych W.P., Jhangri G.S., Leclercq S., et al. An open study of pamidronate in the treatment of refractory ankylosing spondylitis. The Journal of Rheumatology 25 (1998) 714-717
75. Maksymowych W.P., Lambert R., Jhangri G.S., et al. Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. The Journal of Rheumatology 28 (2001) 144-155
76. Akerkar S.M., and Bichile L.S. Pamidronate-a promising new candidate for the management of spondyloarthropathy. Industrial Journal of Medical Sciences 59 (2005) 165-170
77. Maksymowych W.P., Jhangri G.S., Fitzgerald A.A., et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis and Rheumatism 46 (2002) 766-773
78. Adami S., and Zamberlan N. Adverse effects of bisphosphonates. A comparative review. Drug Safety 14 (1996) 158-170
79. Breban M., Gombert B., Amor B., and Dougados M. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis. Arthritis and Rheumatism 42 (1999) 580-581
80. Huang F., Gu J., Zhao W., et al. One-year open-label trial of thalidomide in ankylosing spondylitis. Arthritis and Rheumatism 47 (2002) 249-254
81. Wei J.C., Chan T.W., Lin H.S., et al. Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial. The Journal of Rheumatology 30 (2003) 2627-2631
82. Davis Jr. J.C., Huang F., and Maksymowych W. New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate. Rheumatic Diseases Clinics of North America 29 (2003) 481-494 [viii]
83. Scalapino K.J., and Davis Jr. J.C. The treatment of ankylosing spondylitis. Clinical and Experimental Medicine 2 (2003) 159-165
84. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint, Bone, Spine 71 (2004) 291-295
85. Mintz G., Enriquez R.D., Mercado U., et al. Intravenous methylprednisolone pulse therapy in severe ankylosing spondylitis. Arthritis and Rheumatism 24 (1981) 734-736
86. Peters N.D., and Ejstrup L. Intravenous methylprednisolone pulse therapy in ankylosing spondylitis. Scandinavian Journal of Rheumatology 21 (1992) 134-138
87. Richter M.B., Woo P., Panayi G.S., et al. The effects of intravenous pulse methylprednisolone on immunological and inflammatory processes in ankylosing spondylitis. Clinical and Experimental Immunology 53 (1983) 51-59
88. Bollow M., Braun J., Taupitz M., et al. CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthropathy: indication and follow-up with contrast-enhanced MRI. Journal of Computer Assisted Tomography 20 (1996) 512-521
89. Braun J., Bollow M., Seyrekbasan F., et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. The Journal of Rheumatology 23 (1996) 659-664
90. Hanly J.G., Mitchell M., MacMillan L., et al. Efficacy of sacroiliac corticosteroid injections in patients with inflammatory spondyloarthropathy: results of a 6 month controlled study. The Journal of Rheumatology 27 (2000) 719-722
91. Maugars Y., Mathis C., Berthelot J.M., et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. British Journal of Rheumatology 35 (1996) 767-770
92. Karabacakoglu A., Karakose S., Ozerbil O.M., and Odev K. Fluoroscopy-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with ankylosing spondylitis. Acta Radiologica 43 (2002) 425-427
93. Gunaydin I., Pereira P.L., Daikeler T., et al. Magnetic resonance imaging guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. The Journal of Rheumatology 27 (2000) 424-428
94. Fritz J., König C.W., Gunaydin I., et al. [Magnetic resonance imaging-guided corticosteroid-infiltration of the sacroiliac joints: pain therapy of sacroiliitis in patients with ankylosing spondylitis]. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren 177 (2005) 555-563
95. Pekkafali M.Z., Kiralp M.Z., Basekim C.C., et al. Sacroiliac joint injections performed with sonographic guidance. Journal of Ultrasound in Medicine 22 (2003) 553-559
96. Luukkainen R., Nissilä M., Asikainen E., et al. Periarticular corticosteroid treatment of the sacroiliac joint in patients with seronegative spondylarthropathy. Clinical and Experimental Rheumatology 17 (1999) 88-90